Drug coated balloon catheters for nonvascular strictures

• US 10,668,188 B2
• Filed: 10/14/2013
• Issued: 06/02/2020
• Est. Priority Date: 10/26/2012
• Status: Active Grant

• Current Assignee: Urotronic Inc
• Original Assignee: Urotronic Inc
• Inventors: Wang, Lixiao
• Primary Examiner(s): Azpuru, Carlos A
• Assistant Examiner(s): Hagopian, Casey S
• Application Number:
  US14/438,327
• Publication Number:
  US 20150273117A1
• Time in Patent Office: 2,423 Days
• Field of Search: None
• CPC Class Codes: A61L 2300/41 Anti-inflammatory agents, e.g. NSAIDs
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/45 Mixtures of two or more drugs, e.g. synergistic mixtures
• CPC Class Codes: A61L 2300/602 Type of release, e.g. controlled, sustained, slow
• CPC Class Codes: A61L 2300/606 Coatings
• CPC Class Codes: A61L 2300/802 Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
• CPC Class Codes: A61L 2420/06 Coatings containing a mixture of two or more compounds
• CPC Class Codes: A61L 29/08 Materials for coatings
• CPC Class Codes: A61L 29/085 Macromolecular materials
• CPC Class Codes: A61L 29/16 Biologically active materials, e.g. therapeutic substances A61L29/048 takes precedence
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 13/02 of urine or of the urinary tract, e.g. urine acidifiers
• CPC Class Codes: A61P 13/08 of the prostate
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

Embodiments of the present invention provide a method for treatment of nonvascular body lumen strictures such as benign prostatic hyperplasia (BPH), urethral strictures, ureteral strictures, prostate cancer, esophageal strictures, sinus strictures, biliary tract strictures, asthma and chronic obstructive pulmonary disease (COPD). The method involves delivering, preferably via drug coated balloon catheters, of anti-inflammatory and anti-proliferative drugs (rapamycin or paclitaxel and their analogues) and one or more additives.

Claims

1. A method for treating one of a urethral stricture or a ureteral stricture, the method comprising:

inserting a balloon catheter to a target site in a stricture of a nonvascular body lumen that is one of urethra or ureter, the balloon catheter comprising

a balloon having a uniform circular cross-section perpendicular to a longitudinal direction of the balloon and comprising a uniform coating layer overlying external surfaces of the balloon, wherein the coating layer comprises

a water-soluble first additive that comprises more than one hydroxyl group, wherein the water-soluble first additive has a molecular weight of 50 to 750,

a water-soluble second additive that is different than the first water-soluble additive and that comprises more than one hydroxyl group, wherein the water-soluble second additive has a molecular weight of 750 to 1,000, and

an initial drug load of a hydrophobic therapeutic agent selected from the group consisting of paclitaxel, paclitaxel analogues, rapamycin, rapamycin analogues, and combinations thereof, wherein the weight ratio in the coating layer of the combination of the water-soluble first additive and the water-soluble second additive to the initial drug load is 0.2;

1 to 0.8;

1,

wherein the balloon comprises a polyester, a polyamide, a nylon 12, a nylon 11, a polyamide 12, a block copolymer of a polyether and a polyamide, a polyether block amide, a polyurethane, a block copolymer of a polyether and a polyester, or a combination thereof,

wherein the combination of the water-soluble first and second additives promote rapid release of the hydrophobic therapeutic agent from the balloon at the target site during an inflation period;

inflating the balloon at least until the coating layer contacts walls of the nonvascular body lumen at the target site;

deflating the balloon after the inflation period, wherein the inflation period is from 0.1 minutes to 10 minutes; and

withdrawing the balloon catheter from the nonvascular body lumen, the balloon having thereon a residual drug amount after the withdrawing.

2. The method of claim 1, wherein the coating layer is free of iodine covalent-bonded contrast agents, dyes, oils, and lipids.

3. The method of claim 1, wherein the hydrophobic therapeutic agent is free of enclosure in micelles and liposomes and is free of encapsulation in polymer particles.

4. The method of claim 1, wherein the initial drug load is from 1 to 20 micrograms of the hydrophobic therapeutic agent per square millimeter of the balloon.

5. The method of claim 1, wherein the initial drug load is from 1 to 6 micrograms of the hydrophobic therapeutic agent per square millimeter of the balloon.

6. The method according to claim 1, wherein the method further treats benign prostatic hyperplasia, and the method comprises inserting the balloon catheter to the target site in the stricture of a nonvascular body lumen that is the urethra, wherein the target site in the stricture of the nonvascular body lumen is within a prostate.

7. The method according to claim 1, wherein during inflation the uniform coating layer makes uniform direct pressure contact with the stricture to release the therapeutic agent rapidly with the uniform direct pressure contact.

8. The method according to claim 1, wherein the hydrophobic therapeutic agent is chosen from rapamycin, rapamycin analogues, or a combination thereof.

9. A method of treating a urethral stricture or a ureteral stricture, the method comprising:

inserting a balloon catheter to a target site in a stricture of a urological tract that is a urethra or ureter, the balloon catheter comprising

a balloon having a uniform circular cross-section perpendicular to a longitudinal direction of the balloon and comprising a uniform coating layer overlying external surfaces of the balloon, wherein the coating layer comprises

a water-soluble first additive that comprises more than one hydroxyl group, wherein the water-soluble first additive has a molecular weight of 50 to 750,

a water-soluble second additive that is different than the first water-soluble additive and that comprises more than one hydroxyl group, wherein the water-soluble second additive has a molecular weight of 750 to 1,000, and

a hydrophobic therapeutic agent selected from the group consisting of paclitaxel, paclitaxel analogues, rapamycin, rapamycin analogues, and combinations thereof with an initial drug load of the hydrophobic therapeutic agent, wherein the weight ratio in the coating layer of the combination of the water-soluble first additive and the water-soluble second additive to the initial drug load is 0.2;

1 to 0.8;

1,

wherein the balloon comprises a polyester, a polyamide, a nylon 12, a nylon 11, a polyamide 12, a block copolymer of a polyether and a polyamide, a polyether block amide, a polyurethane, a block copolymer of a polyether and a polyester, or a combination thereof,

wherein the combination of the water-soluble first and second additives promote rapid release of the hydrophobic therapeutic agent from the balloon at the target site during an inflation period;

inflating the balloon at least until the coating layer contacts walls of the target site;

deflating the balloon after the inflation period, wherein the inflation period is from 0.1 minutes to 10 minutes; and

withdrawing the balloon catheter from the target site, the balloon having thereon a residual drug amount of less than 45% of the initial drug load after the withdrawing.

10. The method according to claim 9, wherein the method further treats benign prostatic hyperplasia, and the method comprises inserting the balloon catheter to the target site in the stricture of a nonvascular body lumen that is the urethra, wherein the target site in the stricture of the nonvascular body lumen is within a prostate.

11. The method according to claim 9, wherein during inflation the uniform coating layer makes uniform direct pressure contact with the stricture to release the therapeutic agent rapidly with the uniform direct pressure contact.

12. The method according to claim 9, wherein the hydrophobic therapeutic agent is chosen from rapamycin, rapamycin analogues, or a combination thereof.

13. A method for treating one of a urethral stricture or a ureteral stricture, the method comprising:

inserting a balloon catheter to a target site, wherein the target site is a stricture in one of a urethra and ureter, the balloon catheter comprising

a balloon having a uniform circular cross-section perpendicular to a longitudinal direction of the balloon and comprising a uniform coating layer overlying external surfaces of the balloon, wherein the coating layer comprises

a water-soluble first additive that comprises more than one hydroxyl group, wherein the water-soluble first additive has a molecular weight of 50 to 750,

a water-soluble second additive that is different than the first water-soluble additive and that comprises more than one hydroxyl group, wherein the water-soluble second additive has a molecular weight of 750 to 1,000, and

a hydrophobic therapeutic agent selected from the group consisting of paclitaxel, paclitaxel analogues, rapamycin, rapamycin analogues, and combinations thereof with an initial drug load of from 2 to 6 micrograms of the hydrophobic therapeutic agent per square millimeter of the balloon, wherein the weight ratio in the coating layer of the combination of the water-soluble first additive and the water-soluble second additive to the hydrophobic therapeutic agent is 0.2;

1 to 0.8;

1,

wherein

the balloon comprises a polyester, a polyamide, a nylon 12, a nylon 11, a polyamide 12, a block copolymer of a polyether and a polyamide, a polyether block amide, a polyurethane, a block copolymer of a polyether and a polyester, or a combination thereof,

the coating layer is free of iodine covalent-bonded contrast agents, dyes, oils, and lipids,

the hydrophobic therapeutic agent is free of enclosure in micelles and liposomes and is free of encapsulation in polymer particles, and

the combination of the water-soluble first additive and the water-soluble second additive promotes rapid release of the hydrophobic therapeutic agent from the balloon at the target site during an inflation period;

inflating the balloon at least until the coating layer contacts walls of the target site;

deflating the balloon after the inflation period, wherein the inflation period is from 0.1 minutes to 10 minutes; and

withdrawing the balloon catheter from the target site, the balloon having thereon a residual drug amount of less than 45% of the initial drug load after the withdrawing.

14. The method according to claim 13, wherein the method further treats benign prostatic hyperplasia, and the method comprises inserting the balloon catheter to the target site in the stricture of a nonvascular body lumen that is the urethra, wherein the target site in the stricture of the nonvascular body lumen is within a prostate.

15. The method according to claim 13, wherein during inflation the uniform coating layer makes uniform direct pressure contact with the stricture to release the therapeutic agent rapidly with the uniform direct pressure contact.

16. The method according to claim 13, wherein the hydrophobic therapeutic agent is chosen from rapamycin, rapamycin analogues, or a combination thereof.

17. A method for treating benign prostatic hyperplasia, the method comprising:

inserting a balloon catheter to a target site in a stricture of a nonvascular body lumen that is a urethra, wherein the target site in the stricture of the nonvascular body lumen is within a prostate, the balloon catheter comprising

a balloon having a uniform circular cross-section perpendicular to a longitudinal direction of the balloon and comprising a uniform coating layer overlying a material of the balloon, wherein the coating layer comprises

a water-soluble first additive that comprises more than one hydroxyl group, wherein the water-soluble first additive has a molecular weight of 50 to 750,

a water-soluble second additive that is different than the first water-soluble additive and that comprises more than one hydroxyl group, wherein the water-soluble second additive has a molecular weight of 750 to 1,000,

an initial drug load of a hydrophobic therapeutic agent and the balloon comprises a polyester, a polyamide, a nylon 12, a nylon 11, a polyamide 12, a block copolymer of a polyether and a polyamide, a polyether block amide, a polyurethane, a block copolymer of a polyether and a polyester, or a combination thereof, wherein the weight ratio in the coating layer of the combination of the water-soluble first additive and the water-soluble second additive to the initial drug load is 0.2;

1 to 0.8;

1;

inflating the balloon at least until the coating layer contacts walls of the nonvascular body lumen at the target site to release the hydrophobic therapeutic agent from the balloon at the target site during an inflation period;

deflating the balloon after the inflation period, wherein the inflation period is from 0.1 minutes to 10 minutes; and

withdrawing the balloon catheter from the nonvascular body lumen.

18. The method according to claim 17, wherein during inflation the uniform coating layer makes uniform direct pressure contact with the stricture to release the therapeutic agent rapidly with the uniform direct pressure contact.

19. The method according to claim 17, wherein the hydrophobic therapeutic agent is chosen from rapamycin, rapamycin analogues, or a combination thereof.

20. A method for treating benign prostatic hyperplasia, the method comprising:

inserting a balloon catheter to a target site, wherein the target site is a stricture in a urethra, wherein the target site in the stricture of the nonvascular body lumen is within a prostate, the balloon catheter comprising

a balloon having a uniform circular cross-section perpendicular to a longitudinal direction of the balloon and comprising a uniform coating layer overlying external surfaces of the balloon, wherein the coating layer comprises

a first water-soluble additive that comprises more than one hydroxyl group, wherein the water-soluble first additive has a molecular weight of 50 to 750,

a second water-soluble additive that is different than the first water-soluble additive and that comprises more than one hydroxyl group, wherein the water-soluble second additive has a molecular weight of 750 to 1,000, and

a hydrophobic therapeutic agent selected from the group consisting of paclitaxel, paclitaxel analogues, rapamycin, rapamycin analogues, and combinations thereof with an initial drug load of from 2 to 6 micrograms of the hydrophobic therapeutic agent per square millimeter of the balloon, wherein the weight ratio in the coating layer of the combination of the first water-soluble additive and the second water-soluble additive to the hydrophobic therapeutic agent is 0.2;

1 to 0.8;

1,

wherein

the balloon comprises a polyester, a polyamide, a nylon 12, a nylon 11, a polyamide 12, a block copolymer of a polyether and a polyamide, a polyether block amide, a polyurethane, a block copolymer of a polyether and a polyester, or a combination thereof,

the coating layer is free of iodine covalent-bonded contrast agents, dyes, oils, and lipids,

the hydrophobic therapeutic agent is free of enclosure in micelles and liposomes and is free of encapsulation in polymer particles, and

the first and second water-soluble additive promotes rapid release of the hydrophobic therapeutic agent from the balloon at the target site during an inflation period;

inflating the balloon at least until the coating layer contacts walls of the target site;

deflating the balloon after the inflation period, wherein the inflation period is from 0.1 minutes to 10 minutes; and

withdrawing the balloon catheter from the target site, the balloon having thereon a residual drug amount of less than 45% of the initial drug load after the withdrawing.

21. The method according to claim 20, wherein the hydrophobic therapeutic agent is chosen from rapamycin, rapamycin analogues, or a combination thereof.